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Abstract
Background: The World Health Organization (WHO), like many other organisations around the world, has recognised
the need to use more rigorous processes to ensure that health care recommendations are informed by the best available
research evidence. This is the seventh of a series of 16 reviews that have been prepared as background for advice from
the WHO Advisory Committee on Health Research to WHO on how to achieve this.
Objectives: We reviewed the literature on what constitutes "evidence" in guidelines and recommendations.
Methods: We searched PubMed and three databases of methodological studies for existing systematic reviews and
relevant methodological research. We did not conduct systematic reviews ourselves. Our conclusions are based on the
available evidence, consideration of what WHO and other organisations are doing and logical arguments.
Key question and answers: We found several systematic reviews that compared the findings of observational studies
with randomised trials, a systematic review of methods for evaluating bias in non-randomised trials and several descriptive
studies of methods used in systematic reviews of population interventions and harmful effects.
What types of evidence should be used to address different types of questions?
• The most important type of evidence for informing global recommendations is evidence of the effects of the options
(interventions or actions) that are considered in a recommendation. This evidence is essential, but not sufficient for
making recommendations about what to do. Other types of required evidence are largely context specific.
• The study designs to be included in a review should be dictated by the interventions and outcomes being considered. A
decision about how broad a range of study designs to consider should be made in relationship to the characteristics of
the interventions being considered, what evidence is available, and the time and resources available.
• There is uncertainty regarding what study designs to include for some specific types of questions, particularly for
questions regarding population interventions, harmful effects and interventions where there is only limited human
evidence.
• Decisions about the range of study designs to include should be made explicitly.
• Great caution should be taken to avoid confusing a lack of evidence with evidence of no effect, and to acknowledge
uncertainty.
• Expert opinion is not a type of study design and should not be used as evidence. The evidence (experience or 
observations) that is the basis of expert opinions should be identified and appraised in a systematic and transparent way.
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Background
The World Health Organization (WHO), like many other
organisations around the world, has recognised the need
to use more rigorous processes to ensure that health care
recommendations are informed by the best available
research evidence. This is the seventh of a series of 16
reviews that have been prepared as background for advice
from the WHO Advisory Committee on Health Research
to WHO on how to achieve this.
Recommendations about health care and about interven-
tions or actions that affect health, such as social or envi-
ronmental interventions, can be informed by a wide range
of evidence including randomised trials, non-randomised
comparative studies, descriptive studies, qualitative
research, animal studies and laboratory studies. Discus-
sions of evidence-informed policy and practice can gener-
ate debates regarding what constitutes 'evidence' [1]. A
common understanding of evidence is that "evidence con-
cerns facts (actual or asserted) intended for use in support
of a conclusion" [1]. A fact, in turn, is something known
by experience or observation. An important implication
of this understanding of evidence is that evidence is used
to support a conclusion; it is not the same as the conclu-
sion. Evidence alone does not make decisions.
This understanding of what evidence is has several impli-
cations. Firstly, expert opinion is more than evidence. It
combines facts, interpretation of those facts, and conclu-
sions. There is evidence behind expert opinions. Expert
opinion should be used appropriately by identifying the
facts (experience or observations) that are the basis of the
opinions and appraising the extent to which the facts sup-
port the conclusions [2].
Secondly, not all evidence is equally convincing. How
convincing evidence is (for effects) should be based on
criteria such as: What sort of observations? How well were
they done? How consistent are they? How directly rele-
vant are they? How many are there? How strong is an asso-
ciation?
Thirdly, judgements about how much confidence to place
in different types of evidence (the 'quality' of the evi-
dence) are made either implicitly or explicitly. It is better
to make these judgements systematically and explicitly to
help protect against errors, resolve disagreements, facili-
tate critical appraisal, and communicate information.
This, in turn, requires explicit decisions about what types
of evidence to consider at all.
Fourthly, all evidence is context sensitive, since observa-
tions are made in a specific context. A judgement always
needs to be made about their applicability beyond that
context. It is best to make judgements about applicability
systematically and explicitly, for the same reasons that it is
best to make judgements about the quality of the evidence
systematically and explicitly.
Fifthly, global evidence (i.e. the best evidence from
around the world) is the best starting point for judge-
ments about effects, likely modifying factors, and (some-
times at least) resource utilisation. This argument is based
on the understanding that all evidence is context sensitive
to some extent and, therefore, indirect to some extent.
Decisions based on a subset of observations are more
prone to random errors [3], and judgements about
whether to base a conclusion on a subset of observations
are better informed if the overall observations (all of the
relevant global evidence) are known [4].
Sixthly, local evidence (from the specific setting in which
decisions and actions will be taken) is needed for most
other judgements about what to do, including: the pres-
ence of modifying factors in specific settings, need (prev-
alence, baseline risk or status), values, costs and the
availability of resources.
Recognising the need for both global evidence (of effects)
and local evidence, it is important to be cautious about
developing global recommendations. Nonetheless, global
recommendations are valuable when different local con-
ditions are not likely to lead to different decisions. When
different conditions are likely to lead to different deci-
sions, global frameworks for decisions are still important.
These can reduce unnecessary duplication of efforts. They
are particularly important to support low and middle-
income countries, with limited resources to systematically
develop guidelines, to make context specific decisions by
providing the global evidence, a framework for decisions,
and practical advice for incorporating local evidence.
WHO's focus is on global recommendations and support-
ing its member states to make well-informed decisions.
The primary question that needs to be addressed in this
context is:
• What types of study designs should be used to address
different types of questions about the effects of the differ-
ent options that are considered when making a recom-
mendation?
We therefore have focused this review on questions about
effects, recognising that there are parallel questions
regarding what types of study designs should be used to
address other questions. In addressing this question we
have focused on the validity of different study designs,
assuming that questions about the applicability of the
results of studies to the specific questions of interest will
be similar across different study designs. However, it isHealth Research Policy and Systems 2006, 4:19 http://www.health-policy-systems.com/content/4/1/19
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important to recognise that decisions about what study
designs to include may also be influenced by the extent to
which relevant studies are available that have used study
designs that are most likely to provide valid results. That
is, there may sometimes be a trade-off between including
studies that are more likely to be valid and ones that are
more likely to be directly relevant.
What WHO is doing now
The Guidelines for WHO Guidelines (GWG) state: "It is
recommended that [a] systematic review be undertaken (http:/
/hiru.mcmaster.ca/cochrane/cochrane/hbook.htm)  After the
studies have been identified and critically appraised, and
the evidence synthesised, evidence should be graded. All
evidence, including that on safety, should be clearly laid
out in an evidence table. Meta-analysis should be done
when the data permit. The final results should be pre-
sented in a balance sheet" [5]. The GWG do not address
the choice of study designs for different types of ques-
tions. In practice it is difficult to know what study designs
are considered relevant for different types of WHO recom-
mendations since few WHO guidelines have adhered to
the GWG, few have included a systematic review, and
many do not include references [6,7].
What other organisations are doing
The U.S. Preventive Services Task Force has the following
approach to determining what evidence is admissible:
The topic team determines the bibliographic databases to be
searched and the specific inclusion and exclusion criteria (i.e.,
admissible evidence) for the literature on each key question.
Such criteria typically include study design, population studied,
year of study, outcomes assessed, and length of follow-up. Topic
teams specify criteria on a topic-by-topic basis rather than
adhering to generic criteria. If high-quality evidence is availa-
ble, the topic teams may exclude lower-quality studies. Con-
versely, if higher-quality evidence is lacking, the teams may
examine lower-quality evidence.
If a search finds a well-performed systematic review that
directly addresses the literature on a key question through a
given date, the topic team may use this review to capture the lit-
erature for those dates. The team can then restrict its own
search to dates not covered by the existing systematic review.
The topic team documents these strategies for sharpening focus
– the analytic framework, key questions, and criteria for admis-
sible evidence – in an initial work plan. This work plan is pre-
sented to the Task Force at its first meeting after the topic has
been assigned, allowing the Task Force the opportunity to mod-
ify the direction and scope of the review, as needed [8].
This approach is consistent with other guidance for sys-
tematic reviews, such as those of the Cochrane Health Pro-
motion and Public Health Task Force, which recommends
that:"The study designs to be included in a public health review
should be dictated by the interventions being reviewed (meth-
odological appropriateness), and not vice versa" [9]. There is
also general, although not unanimous, agreement that the
inclusion criteria for a systematic review should specify
the study designs that are acceptable for a specific ques-
tion [10]. However, there are important differences in
both guidance and practice with respect to "how low"
reviewers should go in deciding what evidence to include
[11]. This question is particularly relevant for questions
about the effects of population interventions (public
health, health promotion, health systems and social inter-
ventions) and for evidence of harmful effects [10-20].
The Cochrane Handbook for Systematic Reviews of Inter-
ventions takes a relatively cautious approach: "The more
restrictive authors are in matching questions to particular
aspects of design, the less likely they are to find data specific to
the restricted question. However, reviewing studies that are
unlikely to provide reliable data with which to answer the ques-
tion is a poor use of time and can result in misleading conclu-
sions." [21] Because Cochrane reviews address questions
about the effects of health care, they focus primarily on
randomised trials. The Handbook suggests being cautious
of including non-randomised studies because of the risk
of biased results; the additional work required to identify
and appraise non-randomised studies and keep a review
up-to-date; and the risk of publication bias. It concludes:
"While attention to the risk of bias should guide decisions about
what types of study designs to include in a review, individual
authors and Collaborative Review Groups must decide what
types of studies are best suited to specific questions."
Within the Cochrane Collaboration, several groups have
recommended inclusion of a broader range of study
designs for health systems and public health interventions
and for assessing harmful effects of clinical interventions.
The Cochrane Effective Practice and Organisation of Care
Group (EPOC) argues that: While cluster randomised trials
are the most robust design for quality improvement strategies,
some strategies may not be amenable to randomisation – for
example, mass media campaigns. Under these circumstances,
reviewers may choose to include other designs including quasi-
experimental designs. If a review includes quasi-experimental
studies – for example, interrupted time series designs for evalu-
ating mass media campaigns, the reviewers need to recognise
the weaknesses of such designs and be cautious of over-inter-
preting the results of such studies. Within EPOC, reviewers can
include randomised trials, controlled before and after studies,
and interrupted time series [17].
The Guidelines for Systematic Reviews of Health Promo-
tion and Public Health Interventions Taskforce suggests
including a still broader range of study designs: "A wideHealth Research Policy and Systems 2006, 4:19 http://www.health-policy-systems.com/content/4/1/19
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variety of study designs may be used in the evaluation of public
health activities, ranging from randomized controlled trials
(RCTs) to case studies, with no single method being able to
answer all relevant questions about the effectiveness of all pub-
lic health interventions." [9]
The Cochrane Adverse Effects Subgroup identifies three
possible approaches for incorporating adverse effect data
in a review and summarises the advantages and disadvan-
tages of each of these approaches as summarised in Table
1[18,19].
The U.K. NHS Centre for Reviews and Dissemination pro-
vides the following guidance: "The inclusion criterion speci-
fying the type of study design stems from the desire to base
reviews on the highest quality evidence. There are several areas
of health care which have not been evaluated with methodolog-
ically sound studies. In this situation, studies of methodologi-
cally lower quality may have to be included. Here it is
important to note that the preference for one or another study
design should depend on the nature of questions raised in the
review. Inevitably the decisions regarding inclusion based on
study design will also depend on the availability of suitable
study designs in the literature." [22]
We are not aware of any specific guidance for what study
designs to include for non-human studies, although some
recommendations rely on animal and in vitro studies. For
example, treatment recommendations for emerging dis-
eases, such as SARS or avian influenza (H5N1), for which
case reports may be the only human studies that are avail-
able, may be based on a combination of indirect human
evidence (from the treatment of other similar diseases),
case reports, animal studies and in vitro studies. In gen-
eral, the same principles that apply to human studies can
be applied to animal and in vitro studies [23].
The Guide to Community Preventive Services uses data
from comparative studies – those that compare outcomes
among a group exposed to the intervention versus out-
comes in a concurrent or historical group that was not
exposed or was less exposed – to answer questions about
whether interventions are effective [24]. All comparative
studies are included in its reviews, assessed for their
design suitability and threats to internal and external
validity, and assessed for potential effects of study design
and execution on results.
The Campbell Collaboration does not provide specific
guidance on what study designs should be used to address
different types of questions related to the effects of inter-
ventions in the social, behavioral and educational arenas
[25].
Methods
The methods used to prepare this review are described in
the introduction to this series [26]. Briefly, the key ques-
tions addressed in this paper were vetted amongst the
Table 1: Pros and cons of different approaches for incorporating adverse effect data in a systematic review*
Method Look in the trials/studies 
included in the systematic 
review of benefit.
Look in all retrieved trials/studies of that 
intervention, even in those excluded from the 
analysis of benefit
Look for studies that specifically 
evaluate adverse effects of the 
intervention
Protocol Should usually be the minimum 
recommendation
Studies rejected from analysis of benefit (e.g. because 
beneficial outcomes are measured in a different way, 
which cannot be combined with other studies), may 
be included to allow adverse effect data collection. 
Two sets of inclusion criteria will be needed – for 
benefit, and for adverse effects
Design separate strategy to identify studies 
that report adverse effects, including those 
that do not look at beneficial effects.
Might amount to a separate review nested 
within a traditional Cochrane review
Pros Less demanding on time and 
resources
More comprehensive than just looking at included 
trials
Most comprehensive
Does not require new literature 
search strategy
Can potentially cover a more representative group 
of patients
May be able to evaluate rare, or long-term, 
or previously unrecognized adverse effects
Cons Data may be very limited and 
biased towards common, short-
term harms
Relatively time consuming as full-text articles of all 
potentially relevant studies need checking Data may 
be limited to well-recognized and commonly seen 
adverse effects.
Time and resource intensive
Benefit and harm cannot be compared directly as the 
data come from different sources
Special techniques required in synthesizing 
data from a diverse range of sources
Increased quantity of data but greater risk 
of biased and poor quality data
Benefit and harm cannot be compared 
directly as the data come from different 
sources.
*Copied from reference [18].Health Research Policy and Systems 2006, 4:19 http://www.health-policy-systems.com/content/4/1/19
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authors and the ACHR Subcommittee on the Use of
Research Evidence (SURE). We did not conduct a full sys-
tematic review. We searched PubMed and three databases
of methodological studies (the Cochrane Methodology
Register, the US National Guideline Clearinghouse, and
the Guidelines International Network for existing system-
atic reviews and relevant methodological research that
address these questions. The answers to the questions are
our conclusions based on the available evidence, consid-
eration of what WHO and other organisations are doing,
and logical arguments.
For this review we searched PubMed using (clinical prac-
tice guidelines or public health guidelines or systematic
reviews) and (study designs) and related articles for refer-
ences. We searched the Cochrane Methodology Register
using the key word study design, and we checked the ref-
erence lists of the reports that we retrieved. The searches
were conducted in February and March 2006.
Findings
We found several systematic reviews that compared the
findings of observational studies with randomised trials
[27-33], and a systematic review of methods for evaluat-
ing bias in non-randomised trials [34]. We also found sev-
eral descriptive studies of methods used in systematic
reviews of population interventions and harmful effects.
Systematic reviews of the results of randomised trials com-
pared with observational studies have differed in the
methods they have used, and, to some extent, in their con-
clusions, but have generally found that it is not possible
to predict differences in the size, or even the direction, of
estimates of treatment effects for the same intervention
when it is generated in randomized and non-randomized
studies. However, especially in the more recent reports
[30-33], there is the suggestion that these disparities
decrease when investigators have controlled for known
confounders (between risk/responsiveness and treat-
ment).
The review of methods for evaluating bias in non-ran-
domised trials found six tools that were thought to be suit-
able for use in systematic reviews [34]. Their review of 511
systematic reviews that included non-randomised studies
found that only 169 (33%) assessed study quality. A more
recent survey of methods used in systematic reviews of
adverse effects found that although more than three quar-
ters (185/243) reviews sought to include data from
sources other than randomised controlled trials, fewer
than half (106/256) assessed the quality of the studies
that were included [35].
A study that considered the potential of randomised trials
to provide evidence on specific harms found that of 1727
Cochrane reviews, only 138 included evidence on ≥ 4000
subjects. Of these only 25 (18%) had eligible data on
adverse events, while 77 had no harms data, and 36 had
data on harms that were non-specific or pertained to <
4000 subjects [17]. Thus, while systematic reviews of ran-
domised trials can provide useful information on adverse
effects of clinical interventions, the reporting of adverse
effects in both randomised trials and systematic reviews
needs to be improved.
Descriptive reports of reviews of harmful effects have
found that a significant investment of effort failed to yield
significant new information [18,19,36]. Authors of
reviews of social interventions, on the other hand, have
argued that restricting the study designs that are included
in a review may reduce the value of the review and rein-
force the "inverse evidence law" whereby the least is
known abut the effects of interventions most likely to
influence whole populations. However, this argument
relates more to the importance of mapping out the avail-
able evidence than to producing reliable estimates of the
effects of interventions [11].
Discussion
While there is broad agreement that the study designs to
be included in a review should be dictated by the interven-
tions being reviewed, there is uncertainty regarding what
study designs to include for some specific types of ques-
tions. For any question, as the range of study designs that
are included is broadened, an increasing amount of work
is required to derive decreasingly reliable estimates of the
effects of interventions. A decision about how broad a
range of study designs to consider must be made in rela-
tionship to the characteristics of the interventions, what
evidence is available, and the time and resources availa-
ble.
For any question there is a cut-off point beyond which
broadening the types of studies that are considered
requires a substantial investment of effort that will not
yield additional information that will inform decisions in
a meaningful way. In many cases, it is likely to be prudent
to acknowledge the limits of what is known from a
restricted range of study designs, rather than to invest
additional resources that are unlikely to do more than
confirm the limits of what is known. Whatever decision is
taken about the range of study designs to include should
be made explicit, and great caution should be taken to
avoid confusing a lack of evidence with evidence of no
effect.
Further work
There is a rapidly growing number of reviews and studies
comparing the results of different study designs. High pri-
ority should be given to generating and periodicallyHealth Research Policy and Systems 2006, 4:19 http://www.health-policy-systems.com/content/4/1/19
Page 6 of 7
(page number not for citation purposes)
updating a common data set of studies to update and rec-
oncile different conclusions among these reviews. Priority
should also be given to broadening the scope of these
comparisons to include a wider range of questions and a
wider range of study designs, including animal and labo-
ratory studies. Additional studies, and systematic reviews
of studies, that more rigorously assess the added cost and
value of including broader ranges of study designs would
help to inform decisions about when it is likely to be
important and worthwhile to use more diverse types of
study designs. There is a need to develop more detailed
guidance regarding decisions for which study designs to
include for different types of questions for incorporation
in the Guidelines for WHO Guidelines. This guidance,
which is particularly needed for harms and interventions
targeted at populations, should be based on both empiri-
cal evidence and conceptual arguments.
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